Free tool
FAERS Monitor: Coartem
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022268 or its brand name (Coartem, Artemether, Lumefantrine). Reports on generic versions are filed under their own applications.
Reports
198
Serious
174
88% of reports
Hospitalization
61
Death reported
23
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia22
- vomiting18
- dyspnoea17
- asthenia16
- malaise13
- malaria13
- drug ineffective12
- maternal exposure during pregnancy11
- headache10
- anaemia9
- dizziness9
- pain9
- condition aggravated8
- fatigue8
- swelling face8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2009 | 9 |
| 2010 | 19 |
| 2011 | 12 |
| 2012 | 11 |
| 2013 | 6 |
| 2014 | 12 |
| 2015 | 19 |
| 2016 | 8 |
| 2017 | 18 |
| 2018 | 18 |
| 2019 | 12 |
| 2020 | 13 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malariaSignal | 13 | 1997.6 | 1175.0 | 23,543 |
| maternal exposure during pregnancySignal | 11 | 13.1 | 7.4 | 112 |
| swelling faceSignal | 8 | 13.1 | 6.6 | 78 |
| pyrexiaSignal | 22 | 6.8 | 4.6 | 104 |
| anaemiaSignal | 9 | 5.0 | 2.6 | 25 |
| astheniaSignal | 16 | 4.5 | 2.8 | 41 |
| vomitingSignal | 18 | 4.1 | 2.6 | 40 |
| dyspnoeaSignal | 17 | 3.2 | 2.0 | 24 |
| malaiseSignal | 13 | 3.1 | 1.9 | 17 |
| condition aggravatedSignal | 8 | 2.8 | 1.4 | 8 |
| dizziness | 9 | 1.9 | 1.0 | 3 |
| headache | 10 | 1.7 | 0.9 | 2 |
| pain | 9 | 1.6 | 0.8 | 1 |
| fatigue | 8 | 1.1 | 0.6 | 0 |
| drug ineffective | 12 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.